GB0714447D0 - Cannabidiol for use in the treatment of neurodegenerative conditions - Google Patents

Cannabidiol for use in the treatment of neurodegenerative conditions

Info

Publication number
GB0714447D0
GB0714447D0 GBGB0714447.0A GB0714447A GB0714447D0 GB 0714447 D0 GB0714447 D0 GB 0714447D0 GB 0714447 A GB0714447 A GB 0714447A GB 0714447 D0 GB0714447 D0 GB 0714447D0
Authority
GB
United Kingdom
Prior art keywords
cannabidiol
treatment
neurodegenerative conditions
neurodegenerative
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0714447.0A
Other versions
GB2451254A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to GB0714447A priority Critical patent/GB2451254A/en
Publication of GB0714447D0 publication Critical patent/GB0714447D0/en
Priority to PCT/GB2008/002545 priority patent/WO2009013506A1/en
Publication of GB2451254A publication Critical patent/GB2451254A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
GB0714447A 2007-07-24 2007-07-24 Cannabidiol for use in the treatment of neurodegenerative conditions Withdrawn GB2451254A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0714447A GB2451254A (en) 2007-07-24 2007-07-24 Cannabidiol for use in the treatment of neurodegenerative conditions
PCT/GB2008/002545 WO2009013506A1 (en) 2007-07-24 2008-07-24 Cannabidiol for use in the treatment of transmissible neurodegenerative conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0714447A GB2451254A (en) 2007-07-24 2007-07-24 Cannabidiol for use in the treatment of neurodegenerative conditions

Publications (2)

Publication Number Publication Date
GB0714447D0 true GB0714447D0 (en) 2007-09-05
GB2451254A GB2451254A (en) 2009-01-28

Family

ID=38512800

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0714447A Withdrawn GB2451254A (en) 2007-07-24 2007-07-24 Cannabidiol for use in the treatment of neurodegenerative conditions

Country Status (2)

Country Link
GB (1) GB2451254A (en)
WO (1) WO2009013506A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
WO2017093986A1 (en) * 2015-12-05 2017-06-08 Canabuzz-Med Veterinary composition and methods for production and use
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) * 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents

Also Published As

Publication number Publication date
GB2451254A (en) 2009-01-28
WO2009013506A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
EP2222606A4 (en) Liquid treatment system
PL1975226T3 (en) Liquid treatment composition
HK1148284A1 (en) Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions hif
EP2106814A4 (en) Treatment device
ZA200908799B (en) Presbyopic treatment system
HUE037109T2 (en) Endoxifen for use in the treatment of cancer
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
GB0711342D0 (en) Well treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
EP2106253A4 (en) Tinnitus treatment
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP2197801A4 (en) Wastewater treatment
HK1151971A1 (en) Compounds for use in the treatment of cancer
HK1134911A1 (en) Medicament for the treatment of endometriosis
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
GB0702537D0 (en) Treatment for excessive adiposity
EP2211863A4 (en) Combination therapy
EP2178401A4 (en) Effluent treatment
GB0716784D0 (en) Well treatment
EP2133035A4 (en) Treatment device
IL207906A0 (en) Treatment for ocular-related disorders
GB0700284D0 (en) Combination therapy
ZA200905300B (en) Medicament for the treatment of endometriosis

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)